NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 13 December 2010 The Scottish Medicines Consortium (SMC) has recently concluded that the Glusartel®▼ brand of glucosamine sulphate cannot be recommended for use in NHS Scotland for the relief […]
Category Archives: Musculoskeletal pain
NPC Archive Item: Glucosamine and chondroitin in osteoarthritis: still no good evidence of clinical effectiveness
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 21 October 2010 A network meta-analysis has concluded that glucosamine and chondroitin, given either separately or together, do not affect pain intensity in osteoarthritis (OA) to a clinically meaningful extent […]
NPC Archive Item: CV risk of diclofenac similar to rofecoxib
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 6 July 2010 A large cohort study found that individual NSAIDs have different levels of CV risk. In particular, this study found that diclofenac and rofecoxib were associated with a […]
NPC Archive Item: NICE guidance for low-back pain: acupuncture is an option, but should this be real or simulated?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 1st July 2009 NICE has issued a clinical guideline on the early management of persistent or recurrent low back pain. The guideline includes recommendations for assessment and imaging, provision […]
NPC Archive Item: June Drug Safety Update from MHRA/CHM
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Drug Safety Update is an NHS Evidence accredited provider 11th June 2009 The MHRA and CHM have published the June edition of Drug Safety Update. This issue gives […]
NPC Archive Item: Encouraging prescribing trends for NSAIDs
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 9th March 2009 Since November 2007 there has been a significant change in the prescribing rate of diclofenac (a decline of about 5% of total NSAID items per year) […]
NPC Archive Item: NSAIDs increase risk of death and CV morbidity in people with heart failure
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 6th March 2009 A recent observational study has found that people with heart failure who took NSAIDs, particularly at higher doses, were at substantially greater risk of death or […]
NPC Archive Item: Rofecoxib is associated with an early increase in cardiovascular events, which persists for a year after stopping treatment
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Baron J, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. The Lancet. Early online publication 14th October 2008. DOI:10.1016/S0140-6736(08)61490–7 In the […]
NPC Archive Item: Concomitant use of an SSRI and NSAID increases the risk of an upper GI bleed six times
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2008;27:31–40 The relative risk of […]
NPC Archive Item: EMEA issues new warning for etoricoxib▼, epoetins and ergot-derived dopamine agonists
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Following reviews of the risks and benefits of several drugs, the European Medicines Agency (EMEA) has recommended that: warnings and contraindications should be strengthened for etoricoxib▼ for the treatment […]